PubMed HealthSearch

PubMed · 363642

Acebutolol in angina pectoris: objective assessment using graded treadmill testing.

Abstract

The clinical effects of a new cardioselective beta-adrenergic blocking drug, acebutolol hydrochloride (SECTRAL), were studied in 18 patients with angina pectoris, using graded treadmill testing according to a modified Bruce protocol. Measurements were made in the control state, after two weeks' treatment with placebo and after two more weeks of constant oral dose of the drug. Acebutolol produced a significant increase in the treadmill work performed before the onset of ischemic ECG changes and chest pain. The heart rate and blood pressure responses to exercise were depressed, so that the greater work load was achieved at a lower double product. Graded treadmill testing is a useful method for assessing the efficacy of treatment with a beta-blocking drug.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Kimchi, M S Gotsman, B S Lewis. 1978. Acebutolol in angina pectoris: objective assessment using graded treadmill testing.. https://pubmed.ncbi.nlm.nih.gov/363642/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats.

Disease states such as arthritis may interact with the kinetics of beta-blockers. Acebutolol (AC) is a chiral beta-blocker which is available as a racemate. The beneficial properties of AC, however, is attributed mainly to the S-(+)-enantiomer. The disposition of AC enantiomers and their active, chiral metabolites, diacetolol (DC) were examined after oral administration to healthy and adjuvant-induced arthritic (AA) female Sprague-Dawley rats. Arthritis was induced by tail base injection of Mycobacterium butyricum. Swelling of hind and forepaws were apparent in 10-16 days in AA but not controls. Control and AA rats were sacrificed at 0.5, 1, 2, 4, 6 and 8 h after a 25 mg/kg oral AC dose and blood was collected (n = 6). Significant three to tenfold increases in the initial plasma concentrations (0.5-2 h) of AC were observed in AA. Enantiomers were equally affected, thus AC S:R ratio was not changed. Higher plasma concentrations of the metabolite were only significant at 2 h. The ratio of DC:AC, however, was unaffected by AA. The DC S:R ratio was significantly decreased at 0.5 and 1 h in AA. The limited protein binding of AC (10%) was neither stereoselective nor affected by AA. Reduced intrinsic clearance in AA may be responsible for these observations.

Acebutolol

Efficacy of beta-blocking agents in reducing the number of shocks in patients implanted with first-generation automatic defibrillators.

The efficacy of beta-blockers was tested in 11 patients who avoided sudden death as a result of ventricular tachycardia or fibrillation due to coronary artery disease or non-ischaemic underlying heart disease, after implantation of an automatic defibrillator. Ten patients initially tolerated acebutolol despite prior class III or IV heart failure in six cases; nadolol replaced acebutolol in nine cases for long-term therapy. In these 10 patients, periods of treatment with and without beta-blocking agent were available, making possible a crossover comparison, during a follow-up lasting 31.6 +/- 17.8 months. One hundred and ten shocks were delivered: 14 were considered as probably inappropriate and ruled out, leaving the remaining 96 shocks to be analysed. The monthly rate of shocks was lower during beta-blocking treatment: 0.12 +/- 0.24 vs. 1.09 +/- 1.41 (P = 0.03). While taking beta-blockers, only four patients received shocks, compared to 10 (i.e. all cases) not administered beta-blockers (P less than 0.01). Despite the technical limitations of the study, since only a few spontaneous shocks could be documented on ECG recordings, the efficacy of beta-blockers in preventing occurrence of severe ventricular tachyarrhythmias seems likely, and deserves further investigations using new implanted devices with improved memory functions.

Acebutolol